Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B

INTRODUCTION: Prophylaxis with factor IX (FIX) concentrates, produced by recombinant DNA technology (rFIX) or human plasma-derived concentrates, is the treatment of choice for haemophilia B (HB); rFIX covalently fused to the Fc domain of human immunoglobulin G1 (rFIXFc) allows for prophylaxis/treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Aiello, Andrea, Mancuso, Maria E., Colombo, Alessio, Teruzzi, Cristina, Berto, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677589/
https://www.ncbi.nlm.nih.gov/pubmed/36627960
http://dx.doi.org/10.33393/grhta.2020.2113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677589/
https://www.ncbi.nlm.nih.gov/pubmed/36627960
http://dx.doi.org/10.33393/grhta.2020.2113

Ejemplares similares